The Scientific Journey Behind Ozempic (with Lotte Bjerre Knudsen, Novo Nordisk's Chief Scientific Advisor)
ACQ2 by Acquired
00:00
Exploring the Mechanisms of Lerakotide and Semagotide in Obesity Treatment
Lerakotide and semagotide reduce energy intake by 15% and 30% respectively, primarily targeting the brain to affect hunger, satiety, and the reward system. Animal studies help to pinpoint the receptors in the brain that these medications act on. Patients experience reduced calorie intake, better control of eating, and decreased cravings for savory foods like burgers. Although the exact mechanisms in the brain are not fully understood, the majority of the effect is in the brain. The presence of natural GLP-1 in the brain is not significantly different between individuals with and without diseases, raising questions about how lerakotide and semaglutide with longer half-lives might impact brain penetration.
Transcript
Play full episode
